期刊文献+

表皮生长因子受体抑制剂的皮肤不良反应及处理 被引量:3

Adverse skin reactions to epidermal growth factor receptor inhibitors and their management
原文传递
导出
摘要 表皮生长因子受体抑制剂已成为多种肿瘤生物靶向治疗的重要选择,在肿瘤治疗领域地位日益突出.其可引发多种皮肤不良反应,如:痤疮样皮疹,毛发改变,放射性皮炎,皮肤瘙痒、干燥和皲裂及口腔并发症、指趾甲的改变等.认识这些皮肤不良反应的临床表现,选择适当的药物及时正确地治疗,积极预防不良反应的发生,对确保肿瘤患者治疗的连续性,改善其生活质量有重要的意义. Epidermal growth factor receptor inhibitors (EGFRIs) have become an important option for the targeted treatment of a variety of tumors.However,EGFRIs may cause a series of adverse skin reactions,such as papulopustular (acneiform) eruption,hair and nail changes,radiation dermatitis,pruritus,xerosis,fissure and oral complications.To recognize the manifestations of adverse skin reactions,give timely and appropriate treatment with proper drugs,and to actively prevent the occurrence of adverse reactions are of great value in ensuring continuation of treatment and improving patients' quality of life.
作者 李宁 冯素英
出处 《国际皮肤性病学杂志》 2014年第4期253-255,共3页 International Journal of Dermatology and Venereology
关键词 皮肤病学 不良反应 受体 表皮生长因子 抑制剂 Dermatology Adverse reaction Receptor, epidermal growth factor Inhibitors
  • 相关文献

参考文献19

  • 1Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritusT]. N Engl J Med, 2010, 363(4): 397-398.
  • 2Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus [J]. J Drugs Dennatol, 2010, 9(8): 992-997.
  • 3Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors[J]. Support Care Cancer, 2012, 20(5): 909-921.
  • 4Gerber PA, Kukova G, Buhren BA, et al. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors[J]. Dennatology, 2011, 222(2): 144-147.
  • 5Wollenberg A, Kroth J, Hauschild A, et al. Cutaneous side effects of EGFR inhibitors--appearance and management [J]. Dtsch Med Wochenschr, 2010,135(4): 149-154.
  • 6Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors[J]. Br J Dennatol, 2009, 161 (3): 515-521.
  • 7Eames T, Grabein B, Kroth J, et al. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia [J]. J Eur Acad Dennatol Venereol, 2010, 24 (8): 958-960.
  • 8Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib [J] . Dermatol Online J, 2009,15(3): 4.
  • 9J Boone SL, Rademaker A, Liu D, et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey result [J]. Oncology, 2007, 72 (3-4): 152-159.
  • 10Vezzoli P, Marzano AV, Onida F, et al. Cetuximab-induced acneiform eruption and the response to isotretinoin [J]. Acta Derm Venereol, 2008, 88(1): 84-86.

二级参考文献23

  • 1陈锐深.易瑞沙所致皮疹的中医药治疗[J].华夏医药,2007,2(2):99-100. 被引量:2
  • 2Li J, Peccerillo J, Kaley K, et al. Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP, 2009, 10(3) :338-340.
  • 3Giovannini M, Gregorc V, Belli C, et al. Clinical significance of skin toxicity due to EGFR-targeted therapies. J Oneol, 2009, 84_0051:1-8.
  • 4Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw, 2009, Suppl 1 :S5-21 ; quiz S22-24.
  • 5Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer, 2012, 20(5) :909-921.
  • 6Hassel JC, Kripp M, A1-Batran S, et al, Treatment of epidevnal growth factor receptor antagonist-induced skin rash : results of a survey among German oncologists. Onkologie, 2010, 33 (3) :94-98.
  • 7Saif MW, Kaley K, Lamb L, et al. Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: effective and convenient. JOP, 2010, 11(2) :176-182.
  • 8Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monochmal antibody that retains anti-EGFR activity while minimizing skin toxici- ty. Expert Opin Biol Ther, 2009, 9(9) :1199-1206.
  • 9Xue M, Chow SO, Dervish S, et al. Activated protein C enhances human keratinocyte barrier integrity via sequential activation of epider- mal growth factor receptor and Tie2. J Biol Chem, 2011, 286 ( 8 ) : 6742-6750.
  • 10Gerber PA, Kukova G, Buhren BA, et at. Density of Demodex fol- liculorum in patients receiving epidermal growth factor receptor inhibi- tors. Dermatology, 2011, 222(2):144-147.

共引文献3

同被引文献9

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部